6 May 2020

COMBINE Group is dedicated to the testing and prediction of COVID-19 candidate vaccines efficacy using its in silico UISS platform.

To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline, predicting any therapeutic failure and minimizing undesired effects. We just released (and submitted for possible consideration in one of the top journals in computational medicine) the Universal Immune System Simulator (UISS) for COVID-19, which is potentially ready to be used to predict the outcome of potential vaccination strategies against SARS-CoV-2. The platform is available to all researchers that would like to use it to design and test new candidate vaccines.

The preprint of the article is available following this link:


#sarscov2 #covid19 #insilicotrials